Calcineurin interacts with the serotonin transporter C-terminus to modulate its plasma membrane expression and serotonin uptake

Seimandi, Mathieu; Seyer, Pascal; Park, C Sehwan; Vandermoere, Franck; Chanrion, Benjamin; Bockaert, Joël; Mansuy, Isabelle M; Marin, Philippe

Abstract: Homeostasis of serotonergic transmission critically depends on the rate of serotonin reuptake via its plasma membrane transporter (SERT). SERT activity is tightly regulated by multiple mechanisms, including physical association with intracellular proteins and post-translational modifications, such as phosphorylation, but these mechanisms remain partially understood. Here, we show that SERT C-terminal domain recruits both the catalytic and regulatory subunits of the Ca(2+)-activated protein phosphatase calcineurin (CaN) and that the physical association of SERT with CaN is promoted by CaN activity. Coexpression of constitutively active CaN with SERT increases SERT cell surface expression and 5-HT uptake in HEK-293 cells. It also prevents the reduction of 5-HT uptake induced by an acute treatment of cells with the protein kinase C activator -PMA and concomitantly decreases PMA-elicited SERT phosphorylation. In addition, constitutive activation of CaN in vivo favors 5-HT uptake in the adult mouse brain, whereas CaN inhibition reduces cerebral 5-HT uptake. Constitutive activation of CaN also decreases immobility in the forced swim test, indicative of an antidepressant-like effect of CaN. These results identify CaN as an important regulator of SERT activity in the adult brain and provide a novel molecular substrate of clinical interest for the understanding of increased risk of mood disorders in transplanted patients treated with immunosuppressive CaN inhibitors.

DOI: https://doi.org/10.1523/JNEUROSCI.0076-13.2013

Originally published at:
Seimandi, Mathieu; Seyer, Pascal; Park, C Sehwan; Vandermoere, Franck; Chanrion, Benjamin; Bockaert, Joël; Mansuy, Isabelle M; Marin, Philippe (2013). Calcineurin interacts with the serotonin transporter C-terminus to modulate its plasma membrane expression and serotonin uptake. Journal of Neuroscience, 33(41):16189-16199.
DOI: https://doi.org/10.1523/JNEUROSCI.0076-13.2013
Calcineurin Interacts with the Serotonin Transporter C-Terminus to Modulate Its Plasma Membrane Expression and Serotonin Uptake

Mathieu Seimandi,1,2,3,4* Pascal Seyer,1,2,3,4* C. Sehwan Park,5 Franck Vandermoere,1,2,3,4 Benjamin Chanrion,1,2,3,4 Joël Bockaert,1,2,3,4 Isabelle M. Mansuy,5 and Philippe Marin1,2,3,4

1Centre National de la Recherche Scientifique, UMR-5203, Institut de Génomique Fonctionnelle, F-34094 Montpellier, France, 2Institut National de la Santé et de la Recherche Médicale, U661, F-34094 Montpellier, France, 3Université Montpellier 1, F-34094 Montpellier, France, 4Université Montpellier 2, F-34094 Montpellier, France, and 5Brain Research Institute, Medical Faculty of the University of Zürich and Department of Health Science and Technology of the Swiss Federal Institute of Technology, CH-8057 Zürich, Switzerland

Homeostasis of serotonergic transmission critically depends on the rate of serotonin reuptake via its plasma membrane transporter (SERT). SERT activity is tightly regulated by multiple mechanisms, including physical association with intracellular proteins and post-translational modifications, such as phosphorylation, but these mechanisms remain partially understood. Here, we show that SERT C-terminal domain recruits both the catalytic and regulatory subunits of the Ca2+-activated protein phosphatase calcineurin (CaN) and that the physical association of SERT with CaN is promoted by CaN activity. Coexpression of constitutively active CaN with SERT increases SERT cell surface expression and 5-HT uptake in HEK-293 cells. It also prevents the reduction of 5-HT uptake induced by an acute treatment of cells with the protein kinase C activator β-PMA and concomitantly decreases PMA-elicited SERT phosphorylation. In addition, constitutive activation of CaN in vivo favors 5-HT uptake in the adult mouse brain, whereas CaN inhibition reduces cerebral 5-HT uptake. Constitutive activation of CaN also decreases immobility in the forced swim test, indicative of an antidepressant-like effect of CaN. These results identify CaN as an important regulator of SERT activity in the adult brain and provide a novel molecular substrate of clinical interest for the understanding of increased risk of mood disorders in transplanted patients treated with immunosuppressive CaN inhibitors.

Introduction

Homeostasis of serotonergic transmission critically depends on serotonin (5-HT) reuptake into presynaptic neurons via its plasma membrane transporter SERT, a member of the Na+/Cl−-dependent transporter family (SLC6) (Torres et al., 2003; Murphy and Lesch, 2008). SERT is of major pharmacological and clinical interest as it represents the primary target of several widely prescribed antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) (Jayanthi and Ramamoorthy, 2005; White et al., 2005; Millan, 2006). Moreover, alteration of SERT functional status has been associated with numerous psychiatric disorders, including anxiety and depression (Torres et al., 2003; Murphy and Lesch, 2008). Characterizing the cellular mechanisms that regulate SERT-mediated 5-HT clearance may thus improve our understanding of these disorders and suggest new strategies for therapeutic intervention.

Increasing evidence indicates that multiple regulatory mechanisms control SERT plasma membrane expression and catalytic activity. These include a complex combination of phosphorylation events on SERT Ser, Thr, and Tyr residues and SERT association with accessory/scaffolding proteins (Steiner et al., 2008; Zhong et al., 2012). Many SERT partners have been identified by means of two-hybrid screens and/or communoprecipitation, often based on their previously described interactions with other SLC6 family transporters (Bauman et al., 2000; Haase et al., 2001; Jess et al., 2002; Carneiro and Blakely, 2006; Müller et al., 2006; Ahmed et al., 2008; Carneiro et al., 2008; Steiner et al., 2009). Proteomics strategies have also been successfully used to identify proteins interacting with SERT C terminus, in line with the importance of this domain in the localization and activity of SERT (Larsen et al., 2006). They revealed an association of SERT with the intermediate filament protein vimentin in platelets, which controls the cellular distribution of SERT (Ahmed et al., 2009). We likewise demonstrated that the extreme C terminus of SERT (15 C-terminal amino acids) recruits in brain two PDZ proteins, neuronal nitric oxide synthase (nNOS) and channel interacting PDZ protein, and two proteins of the coat complex II (COPII),
Sec23A and Sec24C (Chanrion et al., 2007). Further studies showed that SERT/nNOS interaction sequesters SERT in intracellular compartments whereas SERT association with Sec24C is required for its export from the endoplasmic reticulum (Chanrion et al., 2007; Sucic et al., 2011), underscoring the power of proteomics approaches to identify novel SERT regulatory mechanisms.

Here, we have used a complementary strategy using the entire C terminus of SERT as bait to identify additional brain partners of SERT recruited by interaction motifs located upstream to its 15 C-terminal amino acids. We found that SERT interacts with both the catalytic and regulatory subunits of calcineurin (CaN), a Ca\(^{2+}\)-calmodulin-activated protein phosphatase enriched in brain, which has been involved in synaptic plasticity and in the mechanism of action of SSRI antidepressants (Mansuy et al., 1998; Malleret et al., 2001). In both models, auto-inhibitory domain (211) in forebrain neurons) mice were described of dox for 100 g of wet food, administered daily for 12 d). Control mice transgene expression was induced by doxycycline (dox) treatment (6 mg/kg food and water

Materials and Methods

Materials. \([^{3}H]\)-5-HT creatine sulfate (95 Ci/mmol), \([^{3}H]\)-citalopram (82 Ci/mmol), \([^{3}H]\)-dihydroxyphenylethylamine dopamine (38.7 Ci/mmol), and \([^{3}H]\)-norepinephrine hydrochloride (14.9 Ci/mmol) were purchased from PerkinElmer. Oligonucleotides were from Eurogentec. The cell culture media and antibodies were from Invitrogen. All chemicals were from Sigma-Aldrich.

Plasmids encoding CA-CaNA (pCMV-Flag/CA-CaNA) and PD-CaNA (pCMV-Flag/PD-CaNA) were kindly provided by Dr. Jean-Antoine Girault (Institut du Fer à Moulin, Paris). The CA-CaNA (constitutively active calcineurin A mutant) construct bears a deletion of the auto-inhibitory domain (398–521). The PD-CaNA (phosphatase-dead calcineurin A mutant) construct bears the same deletion (398–521) and a mutation in the catalytic domain (D\(^{130}\)). The plasmid encoding CaNB (pCMV-CaNB-Flag) was provided by Dr. Alain Lilienbaum (University Paris-Diderot). The plasmids encoding YFP-tagged human SERT (pEYFP/SERT), dopamine transporter (DAT, pEYFP/DAT), and norepinephrine transporter (NET, pEYFP/NET) were kindly provided by Dr. Michael Freimuth (Medical University of Vienna). The pEYFP/SERT and CA-CaN constructs were obtained by mutating the CaN binding site in the human SERT sequence (586/RLIIT to 600/ALAAA).

The mouse monoclonal anti-GFP antibody (mixture of clones 7.1 and 13.1) was from Roche Diagnostics, the rabbit polyclonal anti-GFP antibody from Invitrogen, the rabbit polyclonal anti-SERT antibody from ImmunoStar, the rabbit polyclonal anti-CaNA and CaNB antibody from Millipore Bioscience Research Reagents, the rabbit polyclonal anti-CaNA antibody from Millipore, the mouse monoclonal anti-CaNA antibody and the polyclonal anti-Flag antibody from Sigma-Aldrich, and the rabbit anti-GAPDH antibody from Santa Cruz Biotechnology.

Animals. CN279 (with inducible expression of a constitutively active CaN in forebrain neurons) and 211 (with inducible expression of CaN auto-inhibitory domain (211)) in forebrain neurons) mice were described previously (Mansuy et al., 1998; Malleret et al., 2001). In both models, transgene expression was induced by doxycycline (dox) treatment (6 mg of dox for 100 g of wet food, administered daily for 12 d). Control mice were littermates of double transgenic mice (CN279 or 211) that carried either no transgene or either one of each of the transgenes (rtTA2, tetO-ΔCAM-1, or tetO-211 transgenes). They were similarly treated with dox, as previously described (Mansuy et al., 1998; Malleret et al., 2001). All mice have the same genetic background (C57BL/6) and were backcrossed >15 times.

Mice were maintained in standard laboratory conditions (12 h light/dark cycle with light on at 07:30 A.M.; room temperature 21°C), with food and water ad libitum. Experiments conformed to European ethics standards (86/609-EEC), to decrees of the French National Ethics Com-
For each procedure, the experiments were repeated three times to assess reproducibility.

Analysis of SERT phosphorylation status by MS/MS. YFP-SERT expressed in HEK-293 cells was immunoprecipitated using the GFP-Trap kit (Chromotek). Immunoprecipitated proteins were separated by SDS-PAGE, and the bands corresponding to SERT were digested with trypsin. Peptides were analyzed by nano-LC-FT-MS/MS and searched against the Human Complete Proteome Set database (downloaded on 2012-02-22) as described above, with phosphorylation of Ser, Thr, and Tyr as variable modifications. Ion signals corresponding to phosphorylated peptides were quantified from their extracted ion chromatograms manually extracted using Qual browser version 12.1 (Thermo Fisher Scientific) with a tolerance of 5 ppm for mass deviation and normalized to signals of their nonphosphorylated counterparts.

Coimmunoprecipitation. CHAPS-solubilized proteins from mice brain (1 mg of protein per condition) were incubated overnight at 4°C with 10 μl of anti-SERT antisera or 10 μl of rabbit nonimmune serum. Solubilized proteins from transfected HEK-293 cells (1 mg) were incubated with 1 μg of anti-Flag antibody or control goat IgG. Immunocomplexes were captured by incubation with protein A-Sepharose beads (GE Healthcare) for 1 h at 4°C. Beads were washed three times with 50 mM Tris-HCl, pH 7.4, and immunoprecipitated proteins were analyzed by Western blotting.

Western blotting. Proteins resolved on 10% or 13.5% SDS-PAGE were transferred electrophoretically onto nitrocellulose membranes (Hybond-C; GE Healthcare). Membranes were incubated in blocking buffer (Tris-HCl 50 mM, pH 7.5, NaCl 200 mM, Tween 20, 0.1% and 5% skimmed dried milk) for 1 h at room temperature, and overnight with primary antibodies (rabbit anti-GFP 1/1000; mouse anti-GFP 1/500; rabbit anti-Flag 1/1000; rabbit anti-CaNA and B 1/1000; rabbit anti-CaNA 1/1000; mouse anti-CaNA 1/2000; rabbit anti-GAPDH 1/1000) in blocking buffer at 4°C. They were washed three times with blocking buffer and incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies (1:5000, GE Healthcare) for 1 h at room temperature. Immunoreactivity was detected with an enhanced chemiluminescence method (ECL detection reagent, GE Healthcare).

Luciferase assay. HEK-293 cells electroporated with the NFAT-Luc plasmid in the presence or absence of CaN constructs were lysed with Gly Lysis Buffer (Promega), and luciferase activity in cell lysates was determined using the Bright-Glo Luciferase Assay (Promega), according to the manufacturer’s instructions.

5-HT, dopamine, and norepinephrine uptake assays. HEK-293 cells grown in 96-well culture dishes were washed in HEPES buffer (NaCl 150 mM, KCl 4.2 mM, NaHCO3, 10 mM HEPES, pH 7.4) and incubated for 10 min at 37°C in HEPES buffer containing 100 μM paraglyline and 100 μM ascorbic acid. 5-HT uptake was initiated by the addition of 5-HT (20 nM) under gentle agitation for 30 min at 4°C. After washing from 0.1 to 50 μM (for 10 min at 37°C) and terminated by three washes with ice-cold HEPES buffer containing 10 μM of fluoxetine, followed by cell lysis in 1% SDS. Non-specific 5-HT uptake was determined in the presence of 10 μM of fluoxetine. For 5-HT uptake into cultured mesencephalon neurons, cultures were plated in 12-well culture dishes, pretreated as indicated above, and uptake was initiated by the addition of 100 nM [3H]-5-HT. Non-specific 5-HT uptake was determined in the presence of 50 nM fluoxetine. The radioactivity incorporated into cells was determined by scintillation counting.

Dopamine and norepinephrine uptake was performed in HEK-293 cells using a procedure similar to that used for [3H]-5-HT-5-HT uptake. Uptake was initiated by the addition of [3H]-dopamine (20 nM) or [3H]-norepinephrine hydrochloride (20 nM) and increasing concentrations of cold dopamine or norepinephrine ranging from 0.5 to 30 μM. Determination of non-specific uptake was performed in the presence of 5 μM of GBR12909 and 10 μM of imipramine, respectively.

Biotinylation assay. Biotinylation was performed in transfected HEK-293 cells using the Cell Surface Isolation kit (Pierce), according to the manufacturer’s instructions. Briefly, 48 h after transfection, cells were washed in ice-cold PBS, pH 8.0, and incubated with 1 mg/ml of sulfo-NHS-Ss-biotin under gentle agitation for 30 min at 4°C. After washing, cells were scraped off in 1 ml of lysis buffer and lysates were spun at 8000 × g for 10 min. Clarified cell lysates were then incubated overnight at 4°C with 200 μl of neutravidin-agarose beads. The beads were washed three times in lysis buffer and once in Tris-HCl 50 mM, pH 7.4, and proteins retained on the beads were eluted with 100 μl of SDS sampling buffer. The amount of SERT was analyzed in lysates and eluates (biotinylated fraction) by Western blotting, using the monoclonal anti-GFP antibody.

Preparation of synaptosomes and synaptosomal 5-HT uptake. Synaptosomes were prepared according to the method described by Kolomiytseva et al. (2008). Briefly, brains from C272 or 211 mice and their corresponding controls were gently homogenized with a glass-Teflon homogenizer in 10 volumes of ice-cold buffer containing 50 mM Tris-HCl, pH 7.4, 0.32 mM sucrose, and the protease inhibitor mixture (Roche). The homogenates were centrifuged at 1500 × g for 10 min at 4°C. Supernatants were then centrifuged at 9000 × g for 20 min. The pellets were resuspended in 0.32 mM HEPES buffer, pH 7.4, sucrose solution, and layered over 0.8 mM HEPES-buffered sucrose solution. After centrifugation at 9000 × g for 25 min, the synaptosomal fraction in the 0.8 mM sucrose layer was diluted to obtain a final 0.32 mM sucrose solution and centrifuged at 9500 × g for 20 min. The final pellet (purified synaptosomal fraction) was gently resuspended in Krebs-Ringer bicarbonate medium containing 150 mM NaCl, 4.2 mM KCl, 0.9 mM CaCl2, 0.5 mM MgSO4, 25 mM NaHCO3, 10 mM HEPES, pH 7.4, 5 mM glucose, and protease inhibitors,
and saturated with 95% air/5% CO₂. Protein concentration was determined using the bicinchoninic acid method.

Synaptosomes (0.5 mg per assay) were preincubated with pargyline (100 μM) and ascorbic acid (100 μM) in 0.5 ml of Krebs-Ringer bicarbonate buffer for 10 min at 37°C. 5-HT transport assays (10 min at 37°C) were initiated by the addition of [3H]-5-HT (20 nM) and increasing concentrations of cold 5-HT ranging from 0.05 to 2 μM, and terminated by filtering the samples through 0.3% polyethylenimine-coated glass fiber filters (Whatman GF/C) by using a Brandel cell harvester. Nonspecific [3H]-5-HT uptake was determined in the presence of 10 μM of fluoxetine.

Table 1. Identification of Calcineurin subunits by MALDI-TOF mass spectrometry

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Start</th>
<th>End</th>
<th>M/z (Obs)</th>
<th>Mr (Exp)</th>
<th>Mr (Calc)</th>
<th>δ</th>
<th>Missed cleavage</th>
<th>Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>CaNA (isoform α): 11 peptides; protein score: 132; protein mass: 59,291 Da; peptide coverage: 25%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>143</td>
<td>148</td>
<td>762.49</td>
<td>761.4786</td>
<td>761.4799</td>
<td>0.001</td>
<td>0</td>
<td>K.TLFLLR</td>
</tr>
<tr>
<td>2</td>
<td>30</td>
<td>32</td>
<td>1007.55</td>
<td>1006.5347</td>
<td>1006.5348</td>
<td>0.009</td>
<td>0</td>
<td>K.AVPFFSPHR</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>73</td>
<td>1072.65</td>
<td>1071.6405</td>
<td>1071.6288</td>
<td>0.012</td>
<td>0</td>
<td>R.JITEGASILR</td>
</tr>
<tr>
<td>4</td>
<td>280</td>
<td>289</td>
<td>1117.55</td>
<td>1116.5398</td>
<td>1116.4948</td>
<td>0.045</td>
<td>0</td>
<td>R.AHEAQDAGYR</td>
</tr>
<tr>
<td>5</td>
<td>324</td>
<td>332</td>
<td>1152.55</td>
<td>1151.5477</td>
<td>1151.5393</td>
<td>0.008</td>
<td>0</td>
<td>K.YENINMVIR</td>
</tr>
<tr>
<td>6</td>
<td>33</td>
<td>42</td>
<td>1176.58</td>
<td>1175.5759</td>
<td>1175.5757</td>
<td>0.019</td>
<td>0</td>
<td>K.EVFHDNGKPR</td>
</tr>
<tr>
<td>7</td>
<td>101</td>
<td>112</td>
<td>1247.64</td>
<td>1246.6361</td>
<td>1246.6354</td>
<td>0.002</td>
<td>0</td>
<td>K.LFEVGGSPANTR</td>
</tr>
<tr>
<td>8</td>
<td>113</td>
<td>122</td>
<td>1260.64</td>
<td>1259.6346</td>
<td>1259.6186</td>
<td>0.016</td>
<td>0</td>
<td>R.YLFGLDVYDR</td>
</tr>
<tr>
<td>9</td>
<td>244</td>
<td>254</td>
<td>1369.66</td>
<td>1368.6549</td>
<td>1368.6534</td>
<td>0.003</td>
<td>0</td>
<td>K.DAMPSDANLSINK</td>
</tr>
<tr>
<td>10</td>
<td>488</td>
<td>501</td>
<td>1489.75</td>
<td>1488.7407</td>
<td>1488.6878</td>
<td>0.053</td>
<td>0</td>
<td>K.GLPTGMLPSGVLGGK</td>
</tr>
<tr>
<td>11</td>
<td>425</td>
<td>441</td>
<td>1571.89</td>
<td>1570.8787</td>
<td>1570.8388</td>
<td>0.040</td>
<td>0</td>
<td>K.GLPTGMLPSGVLGGK</td>
</tr>
</tbody>
</table>

CaNB (isoform 1): 5 peptides; protein score: 56; protein mass: 19,244 Da; peptide coverage: 35%

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Start</th>
<th>End</th>
<th>M/z (Obs)</th>
<th>Mr (Exp)</th>
<th>Mr (Calc)</th>
<th>δ</th>
<th>Missed cleavage</th>
<th>Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>117</td>
<td>124</td>
<td>906.43</td>
<td>905.42</td>
<td>905.45</td>
<td>0</td>
<td>0</td>
<td>K.MMVGNNLK</td>
</tr>
<tr>
<td>2</td>
<td>125</td>
<td>134</td>
<td>1187.65</td>
<td>1186.65</td>
<td>1186.62</td>
<td>0</td>
<td>0</td>
<td>K.DTQLQVDVK</td>
</tr>
<tr>
<td>3</td>
<td>135</td>
<td>146</td>
<td>1274.67</td>
<td>1273.66</td>
<td>1273.63</td>
<td>0.04</td>
<td>1</td>
<td>K.TINAXDGGDR</td>
</tr>
<tr>
<td>4</td>
<td>73</td>
<td>84</td>
<td>1369.73</td>
<td>1368.72</td>
<td>1368.69</td>
<td>0.03</td>
<td>0</td>
<td>K.EFEGVOSFSVK</td>
</tr>
<tr>
<td>5</td>
<td>57</td>
<td>72</td>
<td>1783.86</td>
<td>1782.85</td>
<td>1782.83</td>
<td>0.02</td>
<td>0</td>
<td>R.VDVEFTDNGEVDFVK</td>
</tr>
</tbody>
</table>

Table 2. Protein identification by LC-MS/MS

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Start</th>
<th>End</th>
<th>Score</th>
<th>M/z (Obs)</th>
<th>Mr (Exp)</th>
<th>Mr (Calc)</th>
<th>Missed cleavage</th>
<th>Sequence</th>
<th>Modification</th>
</tr>
</thead>
</table>
| CaNA (isoform α): 5 peptides; protein score: 149; protein mass: 59,291 Da; peptide coverage: 15%

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Start</th>
<th>End</th>
<th>Score</th>
<th>M/z (Obs)</th>
<th>Mr (Exp)</th>
<th>Mr (Calc)</th>
<th>Missed cleavage</th>
<th>Sequence</th>
<th>Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>56</td>
<td>63</td>
<td>34.2</td>
<td>458.7583</td>
<td>915.5021</td>
<td>915.5025</td>
<td>0</td>
<td>R.LEESVALR</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>155</td>
<td>163</td>
<td>23.9</td>
<td>593.2999</td>
<td>1184.5853</td>
<td>1184.5866</td>
<td>0</td>
<td>R.HLTEYFTFK</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>101</td>
<td>112</td>
<td>56.0</td>
<td>624.3219</td>
<td>1259.6191</td>
<td>1259.6186</td>
<td>0</td>
<td>R.YLFGLDVYDR</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>113</td>
<td>122</td>
<td>29.6</td>
<td>630.8168</td>
<td>1259.6191</td>
<td>1259.6186</td>
<td>0</td>
<td>R.YLFGLDVYDR</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>425</td>
<td>441</td>
<td>65.0</td>
<td>794.4231</td>
<td>1586.8317</td>
<td>1586.8338</td>
<td>0</td>
<td>K.GLPTGMLPSGVLGGK</td>
<td></td>
</tr>
</tbody>
</table>

CaNA (isoform β): 4 peptides; protein score: 63; protein mass: 59,721 Da; peptide coverage: 11%

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Start</th>
<th>End</th>
<th>Score</th>
<th>M/z (Obs)</th>
<th>Mr (Exp)</th>
<th>Mr (Calc)</th>
<th>Missed cleavage</th>
<th>Sequence</th>
<th>Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>164</td>
<td>172</td>
<td>23.9</td>
<td>593.2999</td>
<td>1184.5853</td>
<td>1184.5866</td>
<td>0</td>
<td>R.HLTEYFTFK</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>110</td>
<td>121</td>
<td>56.0</td>
<td>624.3219</td>
<td>1246.6306</td>
<td>1246.6306</td>
<td>0</td>
<td>K.LFEVGGSPANTR</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>122</td>
<td>131</td>
<td>29.6</td>
<td>630.8168</td>
<td>1259.6191</td>
<td>1259.6186</td>
<td>0</td>
<td>R.YLFGLDVYDR</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>147</td>
<td>157</td>
<td>29.7</td>
<td>668.4056</td>
<td>1334.7966</td>
<td>1334.7962</td>
<td>0</td>
<td>K.ILYPTFLFLR</td>
<td></td>
</tr>
</tbody>
</table>

CaNB (isoform 1): 2 peptides; protein score: 24; protein mass: 19,402 Da; peptide coverage: 11%

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Start</th>
<th>End</th>
<th>Score</th>
<th>M/z (Obs)</th>
<th>Mr (Exp)</th>
<th>Mr (Calc)</th>
<th>Missed cleavage</th>
<th>Sequence</th>
<th>Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>92</td>
<td>107</td>
<td>28.7</td>
<td>585.6269</td>
<td>1753.859</td>
<td>1753.8635</td>
<td>1</td>
<td>K.FDKDGNGYSSAAELR</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>15</td>
<td>31</td>
<td>33.3</td>
<td>615.6347</td>
<td>1843.8824</td>
<td>1843.8841</td>
<td>1</td>
<td>K.EAFSFLDKDGGTITTK</td>
<td></td>
</tr>
</tbody>
</table>

Calmodulin: 2 peptides; protein score: 34; protein mass: 16,827 Da; peptide coverage: 22%

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Start</th>
<th>End</th>
<th>Score</th>
<th>M/z (Obs)</th>
<th>Mr (Exp)</th>
<th>Mr (Calc)</th>
<th>Missed cleavage</th>
<th>Sequence</th>
<th>Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>148</td>
<td>165</td>
<td>24.2</td>
<td>513.0169</td>
<td>2048.0383</td>
<td>2048.0401</td>
<td>1</td>
<td>R.ISFEECAVGGLDHMK</td>
<td></td>
</tr>
</tbody>
</table>

aThe lists of peptides matching with the CaNA (isoform α) and CaNB (isoform 1) sequences are shown. For each peptide identified, the position in protein sequence, Mascot score, and sequence are indicated.

bFor CaNB (isoform 1), peptide 2 did not meet the score requirements set for our experiment but was considered as a genuine identification after manual validation.

[3H]-Citalopram binding. Plasma membrane-enriched fractions (O’Malley et al., 2003) from brains of CN279 or 211 mice or corresponding control mice were incubated with increasing concentrations of [3H]-citalopram ranging from 0.125 to 20 nM for 2 h at 25°C in 500 μl of binding buffer containing 50 mM Tris-HCl, pH 7.4, 120 mM NaCl, and 5 mM KCl. Assays were terminated by rapid filtration of the samples through 0.3% polyethylenimine-coated glass fiber filters (Whatman GF/C) using the Brandel cell harvester. Nonspecific binding was determined in the presence of 10 μM fluoxetine.

Behavioral tests. Behavioral tests were performed by an experimenter blinded to genotype and treatment. The Porsolt Forced Swim Test (FST)
The interaction of SERT with calcineurin depends on calcineurin catalytic activity and Ca\(^{2+}\).

**Figure 2.**

A. HEK-293 cells were transfected with either Flag-tagged CA-CaNA or Flag-tagged PD-CaNA vector, in the absence or presence of Flag-tagged CaNB vector. Total protein extracts were analyzed by Western blotting using a polyclonal anti-Flag antibody. B. HEK-293 cells were cotransfected with pNFAT-Luc reporter plasmid in the absence or presence of CA-CaNA vector. Total protein extracts were analyzed by Western blotting using a polyclonal anti-Flag antibody. C. HEK-293 cells were cotransfected with plasmids encoding wild-type SERT or SERT mutated on the calcineurin interaction site (SERT ΔCt) or cotransfected with plasmids encoding SERT and CA-CaNA (ΔCaN) and treated or not with 10 μM A23187 for 5 min (D). Proteins were immunoprecipitated (IP) with a monoclonal anti-Flag antibody and analyzed by Western blotting using monoclonal anti-Flag (IP) and anti-GFP (Co-IP) antibodies. Representative blots are shown. Immunoreactive signals corresponding to SERT coimmunoprecipitated with CaNA were quantified and normalized to the corresponding CaNA signals in immunoprecipitates. Quantification data are the mean ± SEM of values obtained in three independent experiments. ND, Not detected. *p < 0.05 versus cells expressing SERT and CA-CaNA (ΔCaN).

was performed in a 5 L of plastic container (20 cm diameter) filled (~80% volume) with tap water at 18°C and an Ethovision system (Noldus) for automated video tracking. Recording time was 6 min at a sampling rate of 5 frames per seconds and threshold for immobility at default settings. Both males and females were used, and each mouse was tested only once. Groups consisted of CN279 transgenic mice (n = 10) and their control littermates (mice carrying either the mutation or tTA2 or tetO-ΔCAM-A1 transgene, n = 8), of mixed age and gender: aged (n = 4) and young (n = 14), males (n = 14) and females (n = 4) mice. There was no statistical influence of age or gender.

**Statistics.** Data analysis and statistics were performed by using the GraphPad Prism 5 software. Data on Figures 2, 3, and 4 were analyzed by one-way ANOVA followed by Newman–Keuls or Dunnett’s tests. The Mann–Whitney test was used to analyze the data on Figure 6A. Student’s t test was performed for statistical analysis of behavioral studies.

The SERT C terminus interacts with the catalytic and regulatory subunits of calcineurin

The C-terminal domain of SERT fused to GST (GST-SERT-Ct) was conjugated to glutathione–Sepharose beads and incubated with detergent-solubilized protein extracts from mice brain. Control experiments were performed with beads conjugated to GST alone. Two-dimensional gel analysis of proteins retained by affinity revealed that two additional spots (or trains of spots) were specifically recruited by GST-SERT Ct (Fig. 1A), compared with our previous analyses using a peptide comprising only the 15 C-terminal amino acids of SERT as bait (Chanrion et al., 2007). These proteins were identified by MALDI-TOF mass spectrometry as CaNA (catalytic subunit, also designated as protein phosphatase 2B A) α isoform, and CaNB (regulatory subunit, also designated as protein phosphatase 2B B) isoform 1 (Table 1). Further supporting the association of CaN with SERT, shotgun analysis of proteins pulled-down with GST-SERT Ct by nano-LC-FT-MS/MS identified both α and β isoforms of CaN as well as CaNB isoform 1 (Table 2). Notably, calmodulin (CaM), which is known to tightly associate with CaN heterodimers (Liu, 2009), was also identified as a potential partner of SERT by this shotgun approach.

Recruitment of CaN by SERT-Ct was further validated by Western blotting using a polyclonal antibody recognizing both CaN catalytic and regulatory subunits (Fig. 1B).

Moreover, CaNA was specifically coimmunoprecipitated with native SERT expressed in mice brain (Fig. 1C), indicating that they form a complex in vivo.

We next generated truncation mutants of SERT-Ct and fused them to GST to characterize more precisely the CaN interaction domain within SERT C terminus. Deletion of the 10 N-terminal amino acids of SERT-Ct terminus almost completely prevented recruitment of CaNA and CaNB, whereas the deletion of the 24 C-terminal residues did not prevent association of CaN with SERT-Ct (Fig. 1B), indicating that the 10 N-terminal amino acids of SERT-Ct were necessary and sufficient for its interaction with CaNA and CaNB. Based on existing similarities between the first five amino acids of this sequence (RLIIT) and CaNA binding motifs previously described in several proteins (Aramburu et al., 1998; Li et al., 2007; Takeuchi et al., 2007), we generated several constructs encoding SERT-Ct with one or several of these residues mutated into alanine. We found that replacement of the RLIIT sequence by ALAAA in SERT-Ct abrogated the interaction with CaNA and CaNB (Fig. 1B), thus identifying the R-RIIT sequence as a critical CaN binding motif in the SERT C terminus. We then introduced this modification into the entire SERT sequence.
(SERTΔCaN) to analyze the role of SERT/CaN physical interaction in living cells.

**Interaction of calcineurin with SERT is a dynamic process regulated by calcineurin phosphatase activity and Ca2+**

To further characterize SERT/CaN interaction, we transiently expressed in HEK-293 cells SERT in the absence or presence of a constitutively active CaNA (deleted of the CaM binding domain, CA-CaNA) or a phosphatase-dead, dominant-negative CaNA mutant (PD-CaNA) and of CaNB. As previously observed (Kahl and Means, 2004), coexpression of CaNB was required for expression of both CaNA mutants (Fig. 2A). Therefore, CaNB was systematically coexpressed with CA-CaNA or PD-CaNA in further experiments. We first performed luciferase assays using the NFAT-Rluc reporter gene, to assess CaN activity and to functionally validate the CaNA constructs. Exposure of cells to 10 μM A23187, a Ca2+ ionophore, induced a twofold increase of basal activity in cells expressing NFAT-Rluc, which probably reflected activation of endogenous CaN (Fig. 2B). As expected, CA-CaNA expression elicited a strong luciferase response, which was not further enhanced by exposure of cells to A23187. In contrast, we did not detect any significant increase in luciferase activity in cells expressing PD-CaNA (exposed or not to A23187), compared with cells expressing NFAT-Rluc alone.

We found that SERT was communoprecipitated with both CA-CaNA and PD-CaNA (Fig. 2C). However, the amount of SERT communoprecipitated with PD-CaNA was much lower than that found in CA-CaNA immunoprecipitates (Fig. 2C, lanes 2 and 3), suggesting that CaN activity promotes association of SERT with CaN. Consistent with this finding and further supporting a role of Ca2+ in SERT/CaN interaction, treating cells with A23187 (10 μM, 5 min) increased communoprecipitation of SERT with CA-CaNA (Fig. 2D). As expected, the mutation of the 596RLIIT600 sequence to 596ALAAA600 in the CaN binding site of SERT(SERTΔCaN) strongly reduced its ability to communoprecipitate with CaN. Moreover, communoprecipitation of SERTΔCaN with CaN was further decreased when this mutant SERT was coexpressed with PD-CaNA instead of CA-CaNA (Fig. 2C).

**Calcineurin enhances 5-HT uptake and promotes SERT localization at the plasma membrane in HEK-293 cells**

Coexpression of CA-CaNA (and CaNB) with SERT in HEK-293 cells induced a marked increase in the velocity of 5-HT uptake, compared with cells expressing SERT alone (V<sub>max</sub> = 6.68 ± 1.18 vs 3.77 ± 0.36 pmol/min, p < 0.05; Fig. 3A, C). CA-CaNA expression did not significantly affect the apparent affinity of SERT for 5-HT (K<sub>m</sub> = 2.93 ± 0.47 μM in cells coexpressing SERT and CA-CaNA vs 2.72 ± 0.19 μM in cells expressing SERT alone). Coexpression of CA-CaNA (and CaNB) with DAT did not significantly modify the velocity of dopamine uptake in HEK-293 cells (V<sub>max</sub> = 4.28 ± 0.66 pmol/min vs 3.35 ± 0.61 pmol/min in cells expressing DAT alone, p = 0.73; Fig. 3E), although it slightly but significantly decreased norepinephrine uptake in cells expressing NET (V<sub>max</sub> = 4.66 ± 0.15 pmol/min vs 6.94 ± 0.21 pmol/min in cells expressing NET alone, p < 0.05; Fig. 3F).

In line with the increased 5-HT uptake in cells expressing CA-CaNA, biotinylation experiments indicated an increase in the proportion of SERT at the cell surface in cells coexpressing SERT.
Figure 4. Silencing calcineurin expression and a pharmacological inhibitor of calcineurin decrease 5-HT uptake via SERT. A, HEK-293 cells were transfected with the plasmid encoding SERT and control or CaNA siRNA. Total protein extracts were analyzed by Western blotting using the monoclonal anti-GFP antibody, the polyclonal anti-CaNA antibody, and the anti-GAPDH antibody. C, D, Effect of increasing concentrations of FK506 upon NFAT-Luc reporter activity in HEK-293 cells coexpressing CA-CaNA and SERT. Using the NFAT luciferase reporter system, we showed that FK506 inhibited CaN activity in a concentration-dependent manner (pIC\textsubscript{50} = 8.69 ± 0.24 nM; Fig. 4C) and 5-HT uptake with a similar apparent affinity (pIC\textsubscript{50} = 8.26 ± 0.47 nM; Fig. 4D). Further supporting a modulation of SERT transport activity by endogenous CaN, the CaN inhibitor decreased 5-HT uptake in HEK-293 cells expressing SERT alone in the same concentration range (pIC\textsubscript{50} = 8.36 ± 0.32 nM, Fig. 4E), as well as in mouse mesencephalon neurons in primary culture (67.0 ± 17.1 and 65.3 ± 9.9% basal uptake, measured in neurons treated with 10 and 100 nM FK506, respectively, Fig. 4F).

Calcineurin prevents SERT phosphorylation and inhibition of 5-HT uptake induced by a protein kinase C activator

Several studies have demonstrated that protein kinase C (PKC) activation inhibits 5-HT transport activity of SERT in both recombinant (HEK-293) cells and native (platelets, synaptosomes) systems and that this effect is paralleled by an increase in SERT phosphorylation (Qian et al., 1997; Ramamoorthy et al., 1998; Jayanthi et al., 2005; Samuvel et al., 2005). We thus wondered whether CaN phosphatase activity could affect PKC-mediated SERT regulation. Consistent with these previous findings, we found that a pretreatment of HEK-293 cells expressing SERT alone with the PKC activator β-phorbol 12-myristate 13-acetate (PMA, 100 nM) caused an ∼50% reduction of 5-HT uptake (Fig. 5A). In contrast, PMA did not significantly affect 5-HT uptake in cells coexpressing SERT and CA-CaNA (Fig. 5A), indicating that CaN activity prevents PKC-induced inhibition of SERT transport activity.

Analysis of nano-LC-FT-MS/MS of SERT phosphorylation status in HEK-293 cells coexpressing or not CA-CaNA showed a phosphorylation of SERT at Thr\textsuperscript{616} located in the SITPET sequence of the transporter C terminus (Fig. 5B) and impor-
tant for SERT plasma membrane localization and its uptake function (Ahmed et al., 2009). However, the relative quantification of the corresponding ion signal by mass spectrometry did not reveal any dephosphorylation of this residue in cells expressing CA-CaNA. In PMA-treated cells, we identified an additional phosphorylated peptide in the N-terminal domain of SERT (30VVPTPGKVESQISNGYSAVPSPGAGDDTR60), and the corresponding ion signal was much higher in PMA-treated cells than in cells exposed to vehicle (Fig. 5B). Moreover, expression of CA-CaNA significantly reduced the phosphorylation of this peptide in cells treated with PMA, whereas it did not affect its basal phosphorylation level measured in vehicle-treated cells (Fig. 5C), indicating that CaN prevents PKC-elicited SERT phosphorylation. Unfortunately, we could not unambiguously identify by MS/MS the phosphorylated residue of this peptide, which contains several serines and threonines, as the generated peptide fragments did not allow us to discriminate between a phosphorylation at Ser48 or at Ser52 (Fig. 5B).

Calcineurin enhances 5-HT uptake in mouse brain
To determine whether cerebral 5-HT uptake via SERT is likewise modulated by CaN activity, we compared the velocity of 5-HT uptake in synaptosomes from mice expressing or not CA-CaNA (CN279 mice) or a CaNA auto-inhibitory domain (211 mice) in an inducible manner. Consistent with the data obtained in HEK-293 cells, induction of CA-CaNA expression by dox in CN279 mice significantly increased synaptosomal 5-HT uptake (Vmax = 5.65 ± 0.37 pmol/min vs 3.95 ± 0.11 pmol/min in the corresponding control mice treated with dox, p < 0.05; Km = 0.19 ± 0.05 vs 0.13 ± 0.04 μM, p = 0.210) (Fig. 6A). In line with the increase in 5-HT transport in CN279 mice, we found that [3H]-citalopram binding was significantly increased in plasma membrane-enriched fraction from CN279 mice treated with dox (Bmax = 784 ± 58 vs 637 ± 59 fmol/mg of protein in control mice, p < 0.05; Kd = 5.78 ± 0.85 vs 7.21 ± 0.73 nM, p = 0.223) (Fig. 6C). Conversely, both synaptosomal 5-HT uptake and [3H]-citalopram binding to plasma membrane-enriched fraction were significantly reduced by induction of the CaNA auto-inhibitory domain, compared with the corresponding control mice treated with dox (Vmax of 5-HT uptake = 3.58 ± 0.17 vs 5.09 ± 0.39 pmol/min in control mice, p < 0.05; Km = 0.10 ± 0.02 vs 0.12 ± 0.03 μM, p = 0.313; Bmax = 564 ± 44 vs 712 ± 21 fmol/mg of protein, p < 0.05; Kd = 3.68 ± 0.69 vs 3.35 ± 0.64 nM, p = 0.578) (Fig. 6B, D).

Brain calcineurin expression decreases immobility time in the forced swim test
Collectively, these results support a role for CaN enzymatic activity in the control of cerebral 5-HT uptake. These findings, together with previous observations indicating an important role for CaN phosphatase activity in the mechanisms of action of antidepressants (Crozatier et al., 2007), led us to examine whether expression of CA-CaNA modifies behavior in the FST, a task assessing behavioral despair and used to evaluate the activity of antidepressants in rodents. We found that dox-treated CN279 mice spent approximately twice less time immobile than littermate controls in the FST, specifically during min 3–5 after their initial attempt to escape (Fig. 7), indicating antidepressant-like activity of CaN.

Discussion
The reuptake of 5-HT into presynaptic nerve terminals via SERT is a critical factor that determines the activity of the serotonergic system. Over the past years, an increasing number of studies have pointed the complexity of the cellular mechanisms controlling SERT expression, localization, and transport activity. These include several phosphorylation events driven by various protein kinases and phosphatases and association of SERT with a number of protein partners.
Calcineurin catalytic activity enhances cerebral 5-HT uptake. A, B, [3H]-5-HT uptake in brain synaptosomes from CN279 or 211 mice and from their respective littermate control mice treated with dox for 12 d. Representative dose–response curves obtained in synaptosomes purified from one mouse of each group are shown on the left. An inset shows representative radioactivity precipitated from CN279 control and dox-treated mice. Means of Vmax values (n = 5–7 mice per condition) are represented on the right. **p = 0.05 vs corresponding control. *p = 0.05.

Calcineurin catalytic activity enhances cerebral 5-HT uptake. C, D, [3H]-Citalopram binding measured on membrane preparations from brain of CN279 or 211 mice and their respective controls treated with dox. Representative dose–response curves obtained in membrane-enriched fractions from one mouse of each group are shown on the left. Means of Bmax values (n = 5–7 mice per condition) are represented on the right. *p < 0.05 vs corresponding control. **p < 0.01 vs corresponding control.

Figure 6. Calcineurin catalytic activity enhances cerebral 5-HT uptake. A, B, [3H]-5-HT uptake in brain synaptosomes from CN279 or 211 mice and from their respective littermate control mice treated with dox for 12 d. Representative dose–response curves obtained in synaptosomes purified from one mouse of each group are shown on the left. Means of Vmax values measured in the different groups (n = 5–7 mice per condition) are represented on the right. C, D, [3H]-Citalopram binding measured on membrane preparations from brain of CN279 or 211 mice and their respective controls treated with dox. Representative dose–response curves obtained in membrane-enriched fractions from one mouse of each group are shown on the left. Means of Bmax values (n = 5–7 mice per condition) are represented on the right. *p < 0.05 vs corresponding control. **p < 0.01 vs corresponding control.

Figure 7. Calcineurin decreases immobility time in the forced swim test. Cumulative time spent immobile in CN279 and littermate control mice treated with dox for 12 d before the FST. CN279 mice spent less time immobile overall than controls (n = 10 and 8, respectively, p < 0.05), specifically during min 3–5 after initial attempt to escape. Data are mean ± SEM. *p < 0.05.

Here, we show a physical association of SERT with CaN, a brain-enriched, Ca2+/CaM-activated phosphatase known to modulate key proteins essential for synaptic transmission and neuronal excitability (Baumgärtel and Mansuy, 2012). Consistent with the heterodimeric nature of CaN, which consists of a catalytic CaNA subunit tightly associated with a myristoylated, Ca2+-binding regulatory CaNB subunit, we found that SERT C terminus associates with both CaNA and CaNB. Three isoforms of CaNA, CaNAα, β, and γ and two isoforms of CaNB, CaNB1, and CaNB2, have previously been described, whereas CaNAγ and CaNB2 are found almost exclusively in the testis (Liu, 2009). Thus, only CaNAα, β, and CaNB1 are relevant in the brain. Our MS/MS analyses clearly identified these three isoforms, suggesting that both CaNAα/CaNB1 and CaNAβ/CaNB1 heterodimers can associate with SERT C terminus. In contrast, our proteomic screen did not identify any catalytic subunit of protein phosphatase 2A, suggesting that other domains of SERT are involved in the recruitment of this phosphatase. Further validating the assembly of SERT/CaN complexes in vivo, CaNA was specifically coimmunoprecipitated with native SERT expressed in the adult brain in mice.

Consistent with a tight association of CaN heterodimers with CaM, this protein was also identified in our shotgun analyses of SERT-associated complex, although it was not detected by 2-D gel analysis of proteins pulled down with SERT C terminus. This might be the result of the acidic nature of this protein, which makes its resolution and detection in 2-D gels difficult. The precise architecture of the complex formed by SERT, CaN heterodimer, and CaM also remains to be better defined. However, it is likely that SERT directly interacts with the CaNA subunit, as we identified in the proximal region of SERT C terminus a sequence sharing some similarities with previously identified CaNA binding motifs in various CaN partners (Aramburu et al., 1998), and the mutation of this motif almost completely abolished association of CaN with SERT.

The Ca2+/CaM complex has long been known to modulate 5-HT uptake via SERT (Jayanthi et al., 1994; Yura et al., 1996; Turetta et al., 2004). More recently, Ciccone et al. (2008) have shown that Ca2+/CaM-dependent kinase II controls the transport stoichiometry of SERT by promoting SERT interaction with Syntaxin 1A. Here, we identified another mechanism whereby Ca2+/CaM can affect SERT functional status and which relies on CaN and its physical association with SERT. Interestingly, this interaction was itself dependent on both CaN phosphatase activity and cytosolic Ca2+. Indeed, coimmunoprecipitation experiments in transfected HEK-293 cells showed that CA-CaNA bound more efficiently to SERT than a phosphatase-dead CaNA mutant, and increasing cytosolic Ca2+ concentration further increased association of CA-CaNA to SERT. However, treating cells expressing CA-CaNA with a Ca2+ ionophore did not further enhance its constitutive phosphatase activity. This suggests that Ca2+ can promote and/or stabilize SERT/CaN interaction by ac-
activating CaN and by a CaN-independent mechanism that remains to be elucidated.

Our results, based on a combination of genetic and pharmacological approaches, show that CaN catalytic activity enhances 5-HT transport via SERT and prevents the inhibitory action of PKC upon SERT functional activity. Indeed, the expression of CA-CaNA increased 5-HT uptake in HEK-293 cells, which was of comparable level in cells treated or not with a PKC activator, whereas expression of a phosphatase-dead mutant did not significantly affect the velocity of 5-HT transport.

Induction of expression of CA-CaNA in mice brain likewise increased the velocity of cerebral 5-HT uptake. Corroborating these findings and indicating a role of endogenous CaN in the regulation of SERT activity, both silencing CaNA expression and pharmacological inhibition of CaN by FK506 decreased 5-HT transport activity of SERT in vitro, and brain expression of the CaNA auto-inhibitory domain reduced cerebral 5-HT uptake. Notably, regulation of 5-HT uptake by CaN phosphatase activity correlated with its impact on SERT/CaN interaction. Further supporting a role of SERT/CaN interaction in CaN-elicited SERT functional activity, we found that mutating the CaN binding site in the SERT sequence reduced 5-HT transport. However, we cannot rule out that this mutation also affected SERT functionality via a mechanism independent of CaN binding. Finally, in contrast to the observed enhancement of SERT transport activity by CaN phosphatase activity, we found that coexpression of CA-CaNA with DAT did not affect the velocity of dopamine uptake in HEK-293 cells whereas it reduced the uptake of norepinephrine via NET, indicating that CaN differentially modulates the activity of monoamine transporters.

The molecular events underlying regulation of SERT transport function by CaN remain incompletely elucidated. Our data suggest that it might result, at least in part, from the ability of CaN phosphatase activity to modulate SERT plasma membrane expression. Indeed, expression of CA-CaNA produced a concomitant increase in SERT cell surface expression and 5-HT transport, whereas expression of the CaN auto-inhibitory domain decreased both its plasma membrane expression and 5-HT uptake. In an effort to demonstrate whether SERT itself is a substrate of CaN, we found that one Ser residue located in SERT N-terminal domain was phosphorylated upon exposure of cells to PMA and that expression of CA-CaNA reduced the phosphorylation of this Ser elicted by this treatment. This suggests that the ability of CaN to prevent the downregulation of SERT function caused by PKC activation might result from its capacity to directly dephosphorylate SERT. However, it is unlikely that this phosphorylation event underlies upregulation of SERT activity induced by CaN in the absence of PKC activator, as relative quantification of the corresponding ion signal by mass spectrometry did not reveal further dephosphorylation of this residue in cells expressing CA-CaNA and not treated with PMA. Likewise, CaN did not decrease the phosphorylation level of Thr^{616} located in the SITPET sequence of the transporter C terminus and important for SERT uptake function (Ahmed et al., 2009), indicating that CaN-elicited upregulation of SERT activity does not result from Thr^{616} dephosphorylation. One cannot rule out that MS/MS analysis did not identify all phosphorylated residues in the transporter sequence, including other sites potentially dephosphorylated by CaN, or that CaN dephosphorylates other proteins important for SERT trafficking in and out of the plasma membrane.

Increasing evidence suggests that CaN plays a pivotal role in the control of mood. Treatment of patients after heart transplantation with CaN inhibitors to prevent graft rejection is often accompanied by neuropsychiatric complications, such as depression and anxiety, which can be alleviated by switching the treatment to an mTOR inhibitor (Lang et al., 2009). Systemic administration of CaN inhibitors likewise induces depression-and anxiety-like behaviors in mice, an effect reproduced by local downregulation of CaN in amygdala using short hairpin RNAs targeting CaNA (Bahi et al., 2009). Corroborating these observations and indicating antidepressant-like activity of CaN, induction of CaNA expression in the adult mouse brain (CN279 mice) decreased immobility time in the FST. In contrast, mice constitutively expressing CA-CaNA (CN98 mice) show no variation in immobility time and only increased sensitivity to antidepressant effects (Crozatier et al., 2007). This difference in depression-like behavior might reflect adaptive processes in CN98 mice. Conversely, decreased CaN activity was observed in rats exposed to chronic mild test and inhibition of hippocampal CA3 CaN exacerbated depressive-like behavior in these rats (Zhu et al., 2011). Finally, chronic treatment with an SSRI upregulated CaN protein expression in the hippocampus and mice that overexpress CaN in the hippocampus are more sensitive to the behavioral effects of antidepressants (Crozatier et al., 2007), suggesting that CaN would be an indirect target of antidepressants contributing to their effect upon mood.

Little is known about the cellular mechanisms that underlie the antidepressant-like effects of CaN. Although not expected given the opposite action of CaN and antidepressants upon 5-HT uptake, our results suggest that the behavioral effects of CaN might result from a modulation of SERT plasma membrane density and 5-HT transport activity. This hypothesis is consistent with previous findings indicating a decrease in SERT function in some depressed patients (Parsey et al., 2006a) and a greater risk for depression (associated to a decreased SERT expression) in individuals with the short serotonin transporter allele (Parsey et al., 2006b). They support the notion that a depressive state can be associated with decreased SERT density and/or 5-HT transport and underscore the importance of identifying the concomitant molecular, cellular, and neurochemical changes for a better understanding of the mechanisms leading to an increased risk for depression.

References


